NL-OMON41980已完成不适用
A Phase 1, Single-Center, Single-Blind, Placebo and Propofol Controlled Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous (IV) Infusion Doses of ABP-700 - ANVN-02 (CS0224)
Annovation Biopharma, Inc. (a wholly owned subsidiary of The Medicines Company, Inc.)0 个研究点目标入组 72 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Healthy adult men and/or women between 18 and 45 years of age (inclusive)
排除标准
- •Clinical significant abnormalities at medical research
研究者
相似试验
已完成
不适用
A Phase 1, Single-Center, Double-Blind, Placebo Controlled Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous ABP-700 after a Single Ascending Bolus DoseanesthesiaNL-OMON40883Annovation Biopharma, Inc.60
未知
1 期
A Phase 1, Single-Blind, Randomized, Placebo-Controlled, Single-Dose or Open-Label Multiple-Dose Study of KHK4083 in Healthy Adults and Subjects with Ulcerative ColitisHealthy men and subjects with ulcerative colitisJPRN-jRCT2080223390Kyowa Hakko Kirin Co., Ltd.52
已完成
1 期
A Phase 1, Single-Center, Randomized, Placebo-Controlled, Ascending Single-Dose Study of the Pharmacokinetics, Safety, and Tolerability of Oral XG005 in Healthy VolunteersChronic PainACTRN12617001330336Xgene Pharmaceutical Inc.50
已完成
1 期
A Phase 1 Single-Center, Randomized, Placebo-Controlled, Double-Blind Pilot Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Candidate Topical Antimicrobial (NEO101) in the Reduction of Propionibacterium acnes among Healthy Young Adult MePropionibacterium acnes amongst healthy volunteersSkin - Dermatological conditionsACTRN12606000424505eosil, Inc.30
Unknown
不适用
A Phase 1, Single-Center, Single-Blind, Placebo and Propofol Controlled Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous (IV) Infusion Doses of ABP-700Preliminary safety studyNL-OMON25748Annovation Biopharma, University Medical Center Groningen (UMCG)48